Tamtam Try Tamtam free
Cardinal Health logo

Cardinal Health account plan

Pharmaceuticals medical products distribution

At a glance

Cardinal Health distributes drugs and medical products in the US: $254.2 billion FY2026 revenue, about 63,900 employees.

Cardinal Health, headquartered in Dublin, Ohio, is a healthcare services and products company that distributes pharmaceuticals and medical products to hospitals, health systems, pharmacies, ambulatory surgery centers, laboratories, physician offices and patients at home. It also makes Cardinal Health brand medical products, runs physician-practice management organizations (MSOs), nuclear pharmacies, home diabetes supply and freight management. In the fiscal year to June 30, 2026, revenue was $254.2 billion (+14%), GAAP operating earnings $2,613 million (+15%) and non-GAAP diluted EPS $11.26 (+37%); almost all revenue is in the US. It had about 63,900 employees at June 30, 2026, and is listed on the NYSE (CAH).

Business units

Strategic priorities

Specialty and biopharma growth
Specialty grew over 25% in fiscal 2026 and planning assumes double-digit growth; Biopharma Solutions is targeted at $1 billion by 2028 with 20+% growth, and the 3PL now exclusively services nearly half the cell and gene market.
Expand the MSO platforms
The strategy is to expand the MSOs in GI, urology and oncology and the services they provide; M&A priorities are autoimmune and urology bolt-ons, and The Specialty Alliance reached 33 states.
Grow Cardinal Health brand products
The GMPD improvement plan continues, with Cardinal Health brand growing at least mid-single digits for six quarters and FY2027 GMPD profit guided at $200-220 million.
Earnings growth above the long-term target
FY2027 non-GAAP EPS guidance is $12.40 to $12.60 (+13% to +15%), above the 12% to 14% long-term target, with Other revenue growing 11% to 13%.
Distribution automation
Capex of about $700 million in FY2027 goes mainly to manufacturing and distribution infrastructure and technology, including a new Indianapolis distribution center with robotics opening in 2027.

Latest results

In Q4 FY2026 (quarter to June 30, 2026), revenue was $63.7 billion (+6%), non-GAAP operating earnings $935 million (+30%) and non-GAAP diluted EPS $2.91 (+40%), or $2.60 excluding a one-time $0.31 IEEPA tariff refund benefit. Pharma revenue was $58.8 billion with profit of $645 million (+21%); GMPD profit was $150 million, of which $100 million came from the tariff refund. For FY2027 the company guides to non-GAAP EPS of $12.40 to $12.60, about $1 billion of buybacks, about $700 million of capex and adjusted free cash flow of $3.5-4.0 billion. On October 1, 2026 it signed a binding letter of intent to extend its CVS Health distribution agreement through June 30, 2032, and reaffirmed that guidance.

Investments and deals

MSO acquisitions
ION (December 2024, $1.1 billion), GI Alliance (January 2025, about $2.8 billion), Urology America (May 2025, $381 million) and Solaris Health (November 2025, about $1.9 billion in cash), bringing more than 750 providers across more than 250 practice locations.
Home diabetes supply
ADS was acquired in April 2025 for about $1.0 billion; Strive Medical has been completed and AdaptHealth's Diabetes Health business is being acquired.
Capex and distribution centers
Capex was $649 million in FY2026 on automation, supply chain technology and platforms, with about $700 million expected in FY2027; new Indianapolis and Sacramento distribution centers are planned.
Share buybacks
$1.4 billion of buybacks in FY2026 and a new $5.0 billion authorisation approved on August 4, 2026, taking the total to $6.4 billion.

Challenges and risks

Drug pricing policy
The Inflation Reduction Act caps prices for certain drugs and reduces revenue, alongside the most-favored-nation order and tariffs on imported branded pharmaceuticals; distribution margins are about 1%.
Customer concentration
CVS Health was 28% of FY2026 revenue and the five largest customers 43%; members of Vizient and Premier GPOs were 29%.
Tariffs and commodity costs
GMPD still faces several tariff regimes, generics could face 100% tariffs from 2028, and a protracted Iran conflict raising fuel and resin costs would push GMPD profit to the low end.
MSO regulation and integration
Laws such as Oregon's restrict corporate ownership of physician practices, and the Navista oncology MSO took a $184 million goodwill impairment.
Opioid settlements
$4.3 billion is accrued for national opioid settlements, with most remaining payments through 2038.

What leadership says

“We have simplified our strategy, our structure and how we operate.”

Jason Hollar, Chief Executive Officer · Q4 fiscal 2026 earnings call, August 11, 2026

“we are fairly large in that space, but we still represent a very small percentage of the market.”

Jason Hollar, Chief Executive Officer · Q4 fiscal 2026 earnings call, August 11, 2026, on the MSOs

“we're seeing the market voting for the equity arrangement”

Jason Hollar, Chief Executive Officer · Q3 fiscal 2026 earnings call, April 30, 2026, on oncology MSOs

“Fiscal 2026 was a standout year for Cardinal Health and I am pleased with our strong fourth quarter results.”

Jason Hollar, Chief Executive Officer · Q4 and fiscal 2026 results release, August 11, 2026

Where a supplier can help

Warehouse automation and robotics
Tied to the distribution automation priority and the roughly $700 million FY2027 capex: robotics, warehouse software and supply chain technology suppliers fit the new Indianapolis and Sacramento distribution centers.
Physician-practice services
Tied to MSO expansion: revenue cycle, practice software, compliance and integration services can help MSO platforms absorb acquired GI, urology and oncology practices.
Cell and gene therapy logistics
Tied to specialty and biopharma growth: cold-chain, specialty pharmacy and data tools support the 3PL and the cell and gene therapy pharmacy.
Sourcing and cost resilience in GMPD
Tied to tariff and commodity challenges: alternative sourcing, resin and fuel cost management and manufacturing efficiency suppliers help protect Cardinal Health brand margins.

Tamtam's reading of the priorities and challenges above, not the company's own words.

Selling to companies like Cardinal Health?

Tamtam finds the companies that match your ideal customer, researches each account and tells you who to contact and when.

Find similar companies

Key documents

Read in full by Tamtam; each summary links to the document itself.

Questions about Cardinal Health

What does Cardinal Health do?

Cardinal Health distributes pharmaceuticals and medical products in the US, makes Cardinal Health brand medical products, and runs physician-practice MSOs, nuclear pharmacies, home supply and freight management businesses.

What is Cardinal Health's revenue?

Revenue was $254.2 billion in the fiscal year to June 30, 2026, up 14%, of which Pharma contributed $234,833 million.

How many employees does Cardinal Health have?

About 63,900 at June 30, 2026, of whom about 18,100 outside the US and 2,700 healthcare providers.

Who leads Cardinal Health?

Jason Hollar has been CEO since September 2022 and Aaron Alt CFO since February 2023; Deborah Weitzman leads Pharma and Stephen Mason leads GMPD.

What is Cardinal Health's strategy?

It is growing specialty, biopharma services and physician-practice MSOs, expanding its higher-margin Other businesses, and growing Cardinal Health brand products, while targeting 12% to 14% long-term EPS growth.

Written by Tamtam from the company's own published documents listed above, read in full. Figures are as those documents state them, for the periods they name. (2026-11-17)